Navigation Links
Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR
Date:4/10/2013

tumor xenograft model to better understand the fundamental mechanisms of these tumors," said lead author Huiping Liu, Research Associate, Ben May Department and the Ludwig Center, University of Chicago. "We know that proteins turn genes on and off but so do microRNAs. Our team discovered a small yet influential microRNA known as 30c. When it is present in cells it inhibits metastasis and improves a patient's response to chemotherapy treatment. Our findings may provide a potential new treatment target for this difficult to treat cancer."

From Dr. Bing Ren's laboratory of gene regulation at the Ludwig Institute for Cancer Research in San Diego, post-doctoral fellow Gary Hon, PhD described how adult tissues retain an epigenetic memory of their past development. Further, Dr. Ren tutored conferees about research related to long-range control of gene expression in mammalian cells during an educational session.


'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Ludwig cancer researchers honored among first class of fellows in AACR Academy
2. International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering
3. High-strength material advancements at Wayne State University may lead to new, life-saving steel
4. P&G Beauty & Grooming to present advancements in skin aging & stress sweat at AAD Meeting
5. Stem cell finding could advance immunotherapy for lung cancer
6. Novel coronavirus well-adapted to humans, susceptible to immunotherapy
7. Epigenetics and epidemiology -- hip, hype and science
8. Not by DNA alone: How the epigenetics revolution is fostering new medicines
9. Sick from stress? Blame your mom… and epigenetics
10. Study finds epigenetics, not genetics, underlies homosexuality
11. Epigenetics shapes fate of brain vs. brawn castes in carpenter ants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... mellifera) to the Americas, Mayan bee keepers harvested honey from ... Now, colleagues from the Colegio de la Frontera Sur in ... warn of the imminent demise of stingless bee keeping on ... loss. , "In our initial surveys of bee keepers working ...
... for drug resistance in HIV-infected patients at the time ... life expectancy, according to an article in the Nov. ... , Resistance to antiretroviral therapy, even in patients ... However, genotype resistance testing, which involves looking for the ...
... Covering ship hulls with artificial shark skin could help ... as barnacles on ship hulls is a major cause ... skin offers a structural design that prevents this so ... Applied Sciences, Bremen, Germany, is presenting his work on ...
Cached Biology News:Mayan stingless bee keeping: Going, going, gone? 2Drug resistance testing in treatment-naive HIV patients is cost-effective 2
(Date:2/27/2015)... ADELAIDE, Australia , Feb. 27, 2015 ... data from the DisrupTOR-1 trial of BNC105 in patients ... Symposium in Orlando, Florida . The ... of the City of Hope Comprehensive Cancer Center ... presentation. The new data identifies Ferritin ...
(Date:2/27/2015)...   PureTech , a science and technology R&D ... and technologies in the healthcare sector, announced today the ... Member of the Board of Directors of Sanofi, to ... been a pleasure to know Chris for many years ... working together more closely now," said Dr. Robert ...
(Date:2/26/2015)... 26, 2015   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today reported ... goals, other key objectives, and financial guidance.  Synageva,s ... at 4:30 p.m. EST to review the financial ... participate in today,s call by telephone, please dial ...
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... SAN DIEGO, June 1, 2011 Tioga Pharmaceuticals, Inc. ... granted Fast Track designation by the U.S. Food and ... diarrhea-predominant irritable bowel syndrome (D-IBS). Tioga is conducting a ... conducted under a Special Protocol Assessment agreement with the ...
... 2011 Reportlinker.com announces that a new ... catalogue: Osteosarcoma Therapeutics - ... http://www.reportlinker.com/p0546797/Osteosarcoma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Market Forecasts to 2017 ...
... a new quasiparticle called the "hybrid plasmon polariton" ... circuits and optical computing for the 21st century. ... Lawrence Berkeley National Laboratory (Berkeley Lab) have demonstrated ... on-chip optical communication systems. "We have ...
Cached Biology Technology:FDA Grants Fast Track Designation to Tioga Pharmaceuticals' Asimadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10Nanoscale waveguide for future photonics 2Nanoscale waveguide for future photonics 3Nanoscale waveguide for future photonics 4
... The loxP-amp-loxP cassette is designed ... The prokaryotic promoter gb2 driving the ... modified version of the Em7 promoter. It ... used Tn5 promoter. A synthetic polyadenylation signal ...
... be difficult to achieve in many bacterial ... or more restriction and modification (R-M) systems ... as "foreign". TypeOne™ Restriction Inhibitor provides a ... bacterial strains with type I R-M systems. ...
... most widely used in combination with ... stain nucleic acids following polyacrylamide gel ... Pyronin Y stains RNA red, while ... Chem comp: Dye content ≥ ...
... AMPure is a magnetic bead-based ... no sample transfer, centrifugation or ... small and large PCR extension ... microplates. Agencourt AMPure can easily ...
Biology Products: